Entera Bio Ltd (ENTX)
$1.79
Performance
- $1.72$1.85$1.79
3.91%
Downside
Day's Volatility :7.03%
Upside
3.24%
- $0.52$3.35$1.79
70.95%
Downside
52 Weeks Volatility :84.48%
Upside
46.57%
Returns
| Period | Entera Bio Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | 5.65% | 0.0% |
6 Months | -4.1% | 0.0% |
1 Year | 163.75% | 0.0% |
3 Years | -58.54% | -21.4% |
Highlights
Market Capitalization | 67.9M |
Book Value | $0.24 |
Earnings Per Share (EPS) | -0.26 |
Wall Street Target Price | 10.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -3798.25% |
Return On Assets TTM | -52.34% |
Return On Equity TTM | -101.84% |
Revenue TTM | 57.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -91.5% |
Gross Profit TTM | 33.0K |
EBITDA | -8.5M |
Diluted Eps TTM | -0.26 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.23 |
EPS Estimate Next Year | -0.53 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | -0.06 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 458.66%
Technicals Summary
Sell
Neutral
Buy
Entera Bio Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Entera Bio Ltd | 0.0% | -4.1% | 163.75% | -58.54% | -16.89% |
 Regeneron Pharmaceuticals, Inc. | -11.53% | 7.92% | 21.76% | 83.48% | 256.87% |
 Novo Nordisk A/s | -12.73% | -9.68% | 25.05% | 134.03% | 343.37% |
 Alnylam Pharmaceuticals, Inc. | 5.86% | 71.74% | 59.21% | 32.07% | 248.13% |
 Vertex Pharmaceuticals Incorporated | -3.35% | 12.64% | 28.18% | 152.92% | 164.64% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Entera Bio Ltd | NA | NA | NA | -0.23 | -1.02 | -0.52 | NA | 0.24 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Entera Bio Ltd | Buy | $67.9M | -16.89% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 256.87% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 343.37% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.4B | 248.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 164.64% | 32.84 | -4.74% |
Insights on Entera Bio Ltd
Decreasing Revenue
Revenue is down for the last 2 quarters, 4.48M → 57.0K (in $), with an average decrease of 98.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -1.99M → -2.14M (in $), with an average decrease of 3.7% per quarter
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.1% return, outperforming this stock by 90.6%
Institutional Holdings
Company Information
entera bio ltd. is a biotechnology company located in israel.
Organization | Entera Bio Ltd |
Employees | 17 |
CEO | Ms. Miranda J. Toledano M.B.A. |
Industry | Health Technology |
Discover More
Generations Bancorp Ny Inc
$1.79
-4.28%
Utime Ltd
$1.79
-4.28%
Ncs Multistage Holdings Inc
$1.79
-4.28%
Rent The Runway, Inc
$1.79
-4.28%
Noodles & Co
$1.79
-4.28%
Aam Brentview Dividend Growth Etf
$1.79
-4.28%
Invesco Nasdaq Next Gen 100 Etf
$1.79
-4.28%
Cohen & Steers Tax-advantage
$1.79
-4.28%
Sim Acquisition Corp I-a
$1.79
-4.28%